2014 Press Releases
Keyword Search
 
2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004
DateTitle 
11/12/14WuXi PharmaTech Announces Third-Quarter 2014 Results
SHANGHAI, Nov. 12, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for the third quarter of 2014. Third-Quarter 2014 Highlights Net Revenues Increased 18.3% Year Over Year to $173.6 Million Laboratory Services Net Revenues Grew 16.6% Year Ove... 
Printer Friendly Version
11/12/14WuXi AppTec Announces Enhanced Genomics Services for Chinese Researchers
SHANGHAI, Nov. 12, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced an enhancement to its genomics services. The WuXi Genome Center will provide Chinese researchers who use its gene sequencing services with access to the integrated sequence analysis capabilities of NextCODE ... 
Printer Friendly Version
11/11/14WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2014 Annual General Meeting
SHANGHAI, Nov. 11, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) today announced shareholder resolutions adopted at its annual general meeting of shareholders held in Hong Kong on November 11, 2014. At the meeting, WuXi PharmaTech shareholders approved the re-election of incumbent Class A directors Xiaozhong Liu, Kian Wee Seah, and William R. Keller, each to serve a three-year term. About WuXi PharmaTech WuXi PharmaTech is a leading open-access R&D capability and tec... 
Printer Friendly Version
10/30/14WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax
SHANGHAI, Oct. 30, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced the establishment of a representative office in the Tel Aviv area of Israel.  The new office will promote WuXi's broad platform of integrated R&D services to local customers. It will also collaborate ... 
Printer Friendly Version
10/23/14WuXi Congratulates TaiMed Biologics on Receiving Orphan Drug Designation for Ibalizumab from U.S. FDA
SHANGHAI, Oct. 23, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today congratulates its partner TaiMed Biologics for receiving the Orphan Drug Designation from U.S. FDA for ibalizumab, a humanized monoclonal antibody for the treatment of HIV/AIDS infection. This is a significant milestone that brings ibalizumab one step closer to patients. "We ... 
Printer Friendly Version
10/22/14Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China
Collaboration to address needs of biopharmaceutical companies conducting clinical R&D in China CAMBRIDGE, Mass. and SHANGHAI, Oct. 22, 2014 /PRNewswire/--  Foundation Medicine, Inc. (NASDAQ:FMI) and WuXi PharmaTech (Cayman) Inc. (NYSE:WX) today announced a collaboration to offer Foundation Medicine's comprehensive genomic profiling to biopharmaceutical companies conducting clinical trials in China. Under the terms of the collaboration, Foundation Medicine will license and ... 
Printer Friendly Version
10/21/14WuXi PharmaTech Schedules Third-Quarter 2014 Earnings Release
SHANGHAI, Oct. 21, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, with operations in China and the United States, today announced that it will release financial results for the third quarter of 2014 after the New York Stock Exchange closes on Wednesday, November 12, 2014 (which will be Thursday morning, November 13, 2014 Shanghai time).... 
Printer Friendly Version
10/01/14WuXi PharmaTech Laboratory Testing Division Expands in U.S. With Acquisition of XenoBiotic Laboratories, Inc.
SHANGHAI, Oct. 1, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (WuXi) (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device research and development outsourcing company with operations in China and the United States, announced today that it has acquired XenoBiotic Laboratories, Inc. (XBL), a contract research organization with 27 years of successful operation that provides bioanalytical, drug metabolism, and pharmacokinetic services to the pharmaceutical, animal health, a... 
Printer Friendly Version
09/30/14WuXi PharmaTech Announces Appointment of William R. Keller to Board
SHANGHAI, Sept. 30, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced the appointment of William Robert Keller as an independent director on the Board of Directors. He will serve on the Strategy Committee. Mr. Keller was the general manager of Roche China Ltd. and Shanghai Roche Pharmaceutical Ltd. from 1994 to 2003, and he served ... 
Printer Friendly Version
08/18/14WuXi Facility Passes FDA Inspection for Manufacture of API
... 
Printer Friendly Version
08/13/14WuXi PharmaTech Announces Second-Quarter 2014 Results
SHANGHAI, Aug. 13, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading research and development services company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for the second quarter of 2014.  Second-Quarter 2014 Highlights Net Revenues Increased 14.8% Year Over Year to $163.4 Million Laboratory Services Net Revenues Grew 13.2% Year Over Year to $119.9 M... 
Printer Friendly Version
08/08/14WuXi PharmaTech Announces Appointment of Walter Kwauk to Board
SHANGHAI, Aug. 8, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE:WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced the appointment of Walter Teh-Ming Kwauk as an independent director to the Board of Directors. Mr. Kwauk will serve on the Audit Committee.  Mr. Kwauk is currently a senior consultant at Motorola Solutions (China) Co., Ltd. He serves as a director of Thunder Power Co.... 
Printer Friendly Version
07/22/14WuXi PharmaTech Schedules Second-Quarter 2014 Earnings Release
SHANGHAI, July 22, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release financial results for the second quarter of 2014 after the New York Stock Exchange closes on Wednesday, August 13, 2014 (which will be Thursday morning, August 14, 2014 Shanghai time). The earnings release will be available on the investor relati... 
Printer Friendly Version
07/08/14Director Ying Han Resigns from WuXi Board
SHANGHAI, July 8, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced that Ying Han has stepped down from the WuXi Board of Directors for personal reasons. Ms. Han has served on WuXi's board since 2008.  WuXi has begun a search for a new board member to complete Ms. Han's term of office.  The audit committee, of which Ms. Han was chair... 
Printer Friendly Version
06/23/14WuXi AppTec Webinar on Breakthrough Drugs Draws Strong Attendance
SHANGHAI, June 23, 2014 /PRNewswire/ -- More than 400 life science innovators recently tuned in to a global webinar hosted by WuXi AppTec to gain insights into the advancement of programs that ultimately have been designated by the U.S. Food and Drug Administration as breakthrough therapies. The breakthrough designation applies to specific drugs that treat serious medical conditions and show signs of substantial improvements over available therapies, and it enables their speedy development and c... 
Printer Friendly Version
06/20/14WuXi PharmaTech Toxicology Facility in Suzhou Passes FDA Inspection
SHANGHAI, June 20, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced that its toxicology facility in Suzhou recently passed a surveillance Good Laboratory Practice (GLP) inspection by the U.S. Food and Drug Administration (FDA) with no major observations. This was the first FDA GLP inspection in the facility's five years of operation. T... 
Printer Friendly Version
05/28/14WuXi PharmaTech Begins Operation of New High-Potency API Laboratory
SHANGHAI, May 28, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced that its manufacturing subsidiary, Syn-The-All Pharmaceutical Co., Ltd. (STA), has begun operation of a high-potency active pharmaceutical ingredient (HPAPI) laboratory in Shanghai, thereby adding HPAPI processing to its portfolio of services. The lab will support proce... 
Printer Friendly Version
05/23/14Targos Molecular Pathology GmbH and WuXi PharmaTech to Collaborate in Clinical Biomarker Services and Pathology Training in China
SHANGHAI, May 23, 2014 /PRNewswire/ -- Targos GmbH, a leader in clinical biomarker services, and WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced a strategic biomarker collaboration. Through this collaboration, Targos will provide know-how, services, and the quality standards to support WuXi's bioanalytical work for pharmaceutical customers. The collaboration will fo... 
Printer Friendly Version
05/21/14WuXi PharmaTech Toxicology Facility in Suzhou Passes OECD GLP Inspection
SHANGHAI, May 21, 2014 /PRNewswire/ -- WuXi PharmaTech (NYSE: WX) today announced that its toxicology facility in Suzhou had received a statement of Good Laboratory Practice (GLP) from the Belgium Scientific Institute of Public Health on behalf of the Organization for Economic Cooperation and Development (OECD) after successfully passing three GLP inspections conducted by the Belgium GLP Monitorate. Good Laboratory Practice is a quality system concerned with the organizational processes and cond... 
Printer Friendly Version
05/14/14WuXi PharmaTech Announces First-Quarter 2014 Results
SHANGHAI, May 14, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading research and development services company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for the first quarter of 2014.  First-Quarter 2014 Highlights Net Revenues Increased 11.3% Year Over Year to $146.7 Million Laboratory Services Net Revenues Grew 8.3% Year Over Year to $105.5 Mill... 
Printer Friendly Version
05/13/14WuXi PharmaTech Completes Construction of New Biosafety Testing Facility in Suzhou
SHANGHAI, May 13, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced that construction has been completed on a new biologics biosafety testing facility in Suzhou. The facility consists of 38,000 square feet of laboratories and support areas in a building adjacent to WuXi's GLP preclinical drug safety facility. Operations will begin a... 
Printer Friendly Version
05/12/14WuXi PharmaTech Completes Construction of New Materials Characterization Facility in St. Paul
SHANGHAI, May 12, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, announced today that it has completed an expansion of its materials characterization testing facility in St. Paul, Minnesota. A new 20,000-square-foot laboratory will offer expanded capacity for existing services, like particle identification and extractable/leachable testing, and ... 
Printer Friendly Version
05/08/14WuXi PharmaTech Begins Construction of New R&D and cGMP Manufacturing Campus in Changzhou
SHANGHAI, May 8, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device research and development (R&D) services company with operations in China and the United States, today announced that its manufacturing subsidiary, Syn-The-All (STA) Pharmaceuticals Co., Ltd., has begun construction of a new, fully integrated R&D and cGMP manufacturing site in Changzhou, about 110 miles west of Shanghai.  The new construction aims to ... 
Printer Friendly Version
05/05/14FDA Approves Ibalizumab Manufactured by WuXi PharmaTech for Treatment of Patients on Expanded Access
SHANGHAI and TAIPEI, May 5, 2014 /PRNewswire/ -- WuXi PharmaTech (NYSE: WX) and TaiMed Biologics today announced that the FDA has approved the first batch of the ibalizumab (TMB-355) drug substance and sterile drug product manufactured at WuXi's biologics facilities for ongoing treatment of patients under investigator-sponsored IND's.  This is the first reported FDA approval of a sterile biologics product manufactured in China for use under a U.S. IND, which marks an important milestone of WuXi'... 
Printer Friendly Version
05/01/14WuXi PharmaTech Receives 2013 Lilly Global Supplier Award
SHANGHAI, May 1, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced that the company has received the 2013 Lilly Global Supplier Award. This is the third time that WuXi has been honored with this award from Eli Lilly and Company.  This award was established to recognize the exceptional efforts of Lilly's suppliers in providing the compan... 
Printer Friendly Version
04/30/14WuXi PharmaTech Facilities for Late- and Commercial-Stage Analytical and Stability Testing and Clinical-Trial Materials Manufacturing Pass FDA Audit
SHANGHAI, April 30, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced that its analytical and stability testing facilities, located in Shanghai Waigaoqiao Free Trade Zone, have successfully passed an FDA general GMP inspection. This achievement brings regulatory advantages and potential expedited approval to clients who use these WuXi s... 
Printer Friendly Version
04/29/14WuXi PharmaTech Breaks Ground on New Cell Therapy Manufacturing Facility
SHANGHAI, April 29, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced that it has broken ground on a new facility in Philadelphia for the manufacture of cell therapies. The facility is expected to become operational in the second quarter of 2015.  The new facility will consist of 45,000 square feet of clinical and commercial manufac... 
Printer Friendly Version
04/22/14WuXi PharmaTech Schedules First-Quarter 2014 Earnings Release
SHANGHAI, April 22, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release financial results for the first quarter of 2014 after the New York Stock Exchange closes on Wednesday, May 14, 2014 (which will be Thursday morning, May 15, 2014 Shanghai time). The earnings release will be available on the investor relations s... 
Printer Friendly Version
04/15/14WuXi PharmaTech Files 2013 Annual Report on Form 20-F
SHANGHAI, April 15, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) today announced that it filed its annual report on Form 20-F for the year ended December 31, 2013, with the Securities and Exchange Commission. The annual report can be accessed on WuXi PharmaTech's website at http://www.wuxiapptec.com under the Investor Relations section. WuXi PharmaTech will provide a hard copy of its annual report on Form 20-F containing complete audited financial statements free of charge to it... 
Printer Friendly Version
04/15/14WuXi PharmaTech Announces Management Appointments
Dr. Steve Yang Joins Company as EVP and Chief Operating Officer; Edward Hu Named Chief Investment Officer and Remains Chief Financial Officer SHANGHAI, April 15, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, today announced that Dr. Steve Yang has joined the company as Executive Vice President and Chief Operating Officer. Edward Hu will ... 
Printer Friendly Version
04/07/14WuXi PharmaTech Receives Honorable Mention at 2014 ISPE Facility of the Year Awards
... 
Printer Friendly Version
04/01/14WuXi PharmaTech Corporate Venture Fund Invests in TruTag Security Platform for Drug Safety
SHANGHAI and HONOLULU, April 1, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, and TruTag Technologies, Inc., developer of the leading edible, covert security platform to address the global product counterfeiting challenge, today announced that WuXi Corporate Venture Fund has made an investment in TruTag. In addition, WuXi and TruTag will explore co... 
Printer Friendly Version
03/11/14WuXi PharmaTech and Pacific Biomarkers Announce Collaboration
SHANGHAI and SEATTLE, March 11, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D services company with operations in China and the United States, and Pacific Biomarkers (PBI), a premier biomarker laboratory services provider based in Seattle, today announced a biomarker collaboration.  In a new agreement, PBI will provide access to its extensive menu of validated biomarker assays to support WuXi's integrated clin... 
Printer Friendly Version
03/10/14WuXi PharmaTech Purchases an Illumina HiSeq X Ten Sequencing System
SAN DIEGO and SHANGHAI, March 10, 2014 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that the WuXi Genome Center has purchased an Illumina HiSeq X Ten sequencing system. This new investment will enable WuXi's clinical genomic services to expand from the current target panel, exome, and transcriptome... 
Printer Friendly Version
03/05/14WuXi PharmaTech Announced Fourth-Quarter and Full-Year 2013 Results
... 
Printer Friendly Version
02/26/14WuXi PharmaTech Announces Appointment of Dr. Hua Mu to Head Product Development Service and Partnership Business Unit
SHANGHAI, Feb. 26, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that Dr. Hua Mu has joined WuXi as Senior Vice President of Operations and Global Head of the Product Development Service and Partnership Business Unit, reporting to Dr. Ge Li, Chairman and CEO of WuXi PharmaTech.  Dr. Mu has over 18 years of clinical research and... 
Printer Friendly Version
02/10/14WuXi PharmaTech Schedules Fourth-Quarter and Full-Year 2013 Earnings Release
SHANGHAI, Feb. 10, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release financial results for the fourth quarter and full year of 2013 after the New York Stock Exchange closes on Wednesday, March 5, 2014 (which will be Thursday morning, March 6, 2014 Shanghai time). The earnings release will be available on the inves... 
Printer Friendly Version
01/10/14WuXi PharmaTech Provides Update of 2013 Financial Guidance, to Present at J.P. Morgan Healthcare Conference
SHANGHAI, Jan. 10, 2014 /PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology, and medical-device research and development services company, with operations in China and the United States, today announced that it updated its 2013 financial guidance. The company expects to achieve total revenues for full-year 2013 of approximately $578 million. The company expects diluted EPS for full-year 2013 to slightly exceed the top end of its previous guidance of $1.51-$1.55 (G... 
Printer Friendly Version